Cargando…
SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool
We developed a cost-effectiveness tool “the Adrenal Incidentaloma Intervention Cost Assessment Tool (AI(2)CAT)”. We developed a novel web-based, electronic Adrenal Incidentaloma Management System (eAIMS). We conducted time & motion study utilising the estimated time managing an individual AI cas...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552289/ http://dx.doi.org/10.1210/js.2019-SAT-374 |
_version_ | 1783424569000853504 |
---|---|
author | Hanna, Fahmy W. F. Issa, Basil Lea, Simon George, Cherian Golash, Anourag Firn, Mike Sim, Julius Xydopoulos, Georgios Fordham, Richard Fryer, Anthony |
author_facet | Hanna, Fahmy W. F. Issa, Basil Lea, Simon George, Cherian Golash, Anourag Firn, Mike Sim, Julius Xydopoulos, Georgios Fordham, Richard Fryer, Anthony |
author_sort | Hanna, Fahmy W. F. |
collection | PubMed |
description | We developed a cost-effectiveness tool “the Adrenal Incidentaloma Intervention Cost Assessment Tool (AI(2)CAT)”. We developed a novel web-based, electronic Adrenal Incidentaloma Management System (eAIMS). We conducted time & motion study utilising the estimated time managing an individual AI case. This was undertaken for different phases of our work: (i) pre-intervention, (ii) The implementation of case prioritisation strategy + utilisation of eAIMS and (iii) future proactive case identification and streamlining into low- and high-risk groups. Projecting our unit’s case load to a UK-wide context, there could be 50,000 new cases PA/year. Utilising the AI2CAT tool and the time and motion analysis data, demonstrated that introducing the eAIMS system in combination with the MDT prioritisation process (Phase 2) reduced the number of tasks required in the AI management pathway. This resulted in a reduction in the hands-on total time taken (from AI identification to MDT decision) by 48.6%. Utilising standardised staff costs, hands-on time was reduced by 28.2% of total costs/patient. Conclusion: We have developed an electronic management system for AI, together with a cost-effectiveness tool to measure the potential cost implications. The combined approach of using the eAIMS system together with a prioritisation strategy resulted in reduced staff hands-on time and cost per case. |
format | Online Article Text |
id | pubmed-6552289 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65522892019-06-13 SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool Hanna, Fahmy W. F. Issa, Basil Lea, Simon George, Cherian Golash, Anourag Firn, Mike Sim, Julius Xydopoulos, Georgios Fordham, Richard Fryer, Anthony J Endocr Soc Adrenal We developed a cost-effectiveness tool “the Adrenal Incidentaloma Intervention Cost Assessment Tool (AI(2)CAT)”. We developed a novel web-based, electronic Adrenal Incidentaloma Management System (eAIMS). We conducted time & motion study utilising the estimated time managing an individual AI case. This was undertaken for different phases of our work: (i) pre-intervention, (ii) The implementation of case prioritisation strategy + utilisation of eAIMS and (iii) future proactive case identification and streamlining into low- and high-risk groups. Projecting our unit’s case load to a UK-wide context, there could be 50,000 new cases PA/year. Utilising the AI2CAT tool and the time and motion analysis data, demonstrated that introducing the eAIMS system in combination with the MDT prioritisation process (Phase 2) reduced the number of tasks required in the AI management pathway. This resulted in a reduction in the hands-on total time taken (from AI identification to MDT decision) by 48.6%. Utilising standardised staff costs, hands-on time was reduced by 28.2% of total costs/patient. Conclusion: We have developed an electronic management system for AI, together with a cost-effectiveness tool to measure the potential cost implications. The combined approach of using the eAIMS system together with a prioritisation strategy resulted in reduced staff hands-on time and cost per case. Endocrine Society 2019-04-30 /pmc/articles/PMC6552289/ http://dx.doi.org/10.1210/js.2019-SAT-374 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Adrenal Hanna, Fahmy W. F. Issa, Basil Lea, Simon George, Cherian Golash, Anourag Firn, Mike Sim, Julius Xydopoulos, Georgios Fordham, Richard Fryer, Anthony SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool |
title | SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool |
title_full | SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool |
title_fullStr | SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool |
title_full_unstemmed | SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool |
title_short | SAT-374 Adrenal Incidentaloma Management: Development of a Cost-Effectiveness Tool |
title_sort | sat-374 adrenal incidentaloma management: development of a cost-effectiveness tool |
topic | Adrenal |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552289/ http://dx.doi.org/10.1210/js.2019-SAT-374 |
work_keys_str_mv | AT hannafahmywf sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT issabasil sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT leasimon sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT georgecherian sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT golashanourag sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT firnmike sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT simjulius sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT xydopoulosgeorgios sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT fordhamrichard sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool AT fryeranthony sat374adrenalincidentalomamanagementdevelopmentofacosteffectivenesstool |